NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study of Mast Cell Precursors

Completed

Conditions: Mastocytosis
Healthy Volunteer

First Posted Date: 1999-11-04

Last Posted Date: 2022-11-07

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 202

Registration Number: NCT00001756

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Cytokine Production Patterns in Patients With Systemic Mastocytosis Compared With Atopic Dermatitis and Healthy Individuals

Completed

Conditions: Atopic Dermatitis
Healthy
Mastocytosis

First Posted Date: 1999-11-04

Last Posted Date: 2007-12-13

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 40

Registration Number: NCT00001760

Locations: 🇺🇸
National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States

Study of Patients With Strongyloides Stercoralis Infection

Completed

Conditions: HIV Infection
Nematode Infection
Strongyloidiasis

First Posted Date: 1999-11-04

Last Posted Date: 2009-08-25

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 650

Registration Number: NCT00001245

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Drug Interactions Among Anti-HIV Agents

Phase 1

Completed

Conditions: HIV Infection

First Posted Date: 1999-11-04

Last Posted Date: 2008-03-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 22

Registration Number: NCT00001766

Locations: 🇺🇸
National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States

Pharmacodynamics of Intermittent IL-2 Infusions in HIV Seropositive Patients

Phase 2

Completed

Conditions: HIV Infection

First Posted Date: 1999-11-04

Last Posted Date: 2008-03-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 36

Registration Number: NCT00001474

Locations: 🇺🇸
National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States

Stem Cell Transplant Following Low-Intensity Chemotherapy to Treat Chronic Granulomatous Disease

Phase 1

Completed

Conditions: Chronic Granulomatous Disease

First Posted Date: 1999-11-04

Last Posted Date: 2008-03-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 60

Registration Number: NCT00001765

Locations: 🇺🇸
National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States

Subcutaneously Administered Interleukin-2 Therapy in HIV-Infected Patients

Phase 2

Completed

Conditions: HIV Infection

First Posted Date: 1999-11-04

Last Posted Date: 2008-03-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 80

Registration Number: NCT00001357

Locations: 🇺🇸
National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States

Continued Antiretroviral Therapy With Abacavir, Amprenavir and Efavirenz

Phase 2

Completed

Conditions: HIV Infection

First Posted Date: 1999-11-04

Last Posted Date: 2008-03-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 25

Registration Number: NCT00001758

Locations: 🇺🇸
National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States

A Phase I/II Study of the Combination of Azidothymidine and Interleukin-2 (IL-2) in the Treatment of HIV-Infected Patients

Phase 2

Completed

Conditions: HIV Infection

First Posted Date: 1999-11-04

Last Posted Date: 2008-03-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 73

Registration Number: NCT00001282

Locations: 🇺🇸
National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States

Etanercept to Treat Wegener's Granulomatosis

Phase 2

Completed

Conditions: Vasculitis
Wegener's Granulomatosis

First Posted Date: 1999-11-04

Last Posted Date: 2008-03-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 60

Registration Number: NCT00001901

Locations: 🇺🇸
National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy